/CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announces that effective January 6, 2016
Brian Neill has tendered his resignation from the Board of Biosign. He states "it is with reluctance that I am now leaving the Board of Biosign, as so much work has been done turning the company around into a Software as Service Company with a revenue stream from its operations in Germany. However I am also involved in a software company in the health care industry so to prevent any perceived or potential conflicts of interest, I thought it prudent to resign at this time."
TORONTO, Jan. 11, 2016 Dr. Gross, CEO of Biosign has thanked Brian for his time on the Board, noting that he received no remuneration during his tenure, and states "we will now actively recruit for other suitably equipped directors to help us grow this company in our chosen specialty field, providing software that enables better care to be provided for people in their own homes."
Biosign notes that at present the software Aiomed is operating in Germany in care facilities run by Caritas, Germany's largest Health care operator.
About Biosign Technologies Inc. (TSXV: BIO) Biosign is a developer of world class healthcare software solutions targeted at the Home Care markets with operations in Canada and Germany.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information: Biosign Contact Information: Michael Gross, CEO and Chairman, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 201, Email: email@example.com